Osteoclast enlargement in endstage renal disease

Genomic Damage in Endstage Renal Disease—Contribution of Uremic Toxins

Patients with end-stage renal disease (ESRD), whether on conservative, peritoneal or hemodialysis therapy, have elevated genomic damage in peripheral blood lymphocytes and an increased cancer incidence, especially of the kidney. The damage is possibly due to accumulation of uremic toxins like advanced glycation endproducts or homocysteine. However, other endogenous substances with genotoxic pro...

Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial.

BACKGROUND Excess cardiovascular mortality has been documented in chronic haemodialysis patients. Oxidative stress is greater in haemodialysis patients with prevalent cardiovascular disease than in those without, suggesting a role for oxidative stress in excess cardiovascular disease in haemodialysis. We investigated the effect of high-dose vitamin E supplementation on cardiovascular disease ou...

Original Research Reports Interplay ofAnxiety andDepressionWithQuality of Life in Endstage Renal Disease

Background: Endstage renal disease (ESRD) is increasingly being recognized as a major public health issue globally. Planning of intervention measures is preferably hinged on what is known about outcome parameters. Objectives: This study investigated the influence of anxiety with depression and psychosocialand treatment-related correlates on quality of life (QOL) in ESRD. Methodology: Overall, 1...

[Primary hyperoxaluria with endstage renal failure in an infant].

OBJECTIVE To report a case of an infant with endstage renal failure caused by primary hyperoxaluria. METHODS The review of the literature showed the rarity of the disease. In France, the prevalence is about 1.05/million and the incidence rate is 0.12/million/year. A survey, performed in international specialized centers in 1999, documented 78 cases in infants; in 14% of them the initial onset...

Does medical insurance matter in the progression to endstage renal disease among patients with lupus nephritis?